Opiant Pharmaceuticals market cap is $32.2 m, and annual revenue was $40.52 m in FY 2019

Opiant Pharmaceuticals Net income (Q2, 2020)-216.2 K

Opiant Pharmaceuticals EBIT (Q2, 2020)-231.6 K

Opiant Pharmaceuticals Cash, 30-Jun-202030.5 M

Opiant Pharmaceuticals EV2.2 M

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Revenue | 18.4m | 14.0m | 40.5m |

| (24%) | ||

## Cost of goods sold | |||

## Gross profit | 40.5m | ||

| 100% | ||

## Sales and marketing expense | 1.7m | 213.9k | 611.6k |

## R&D expense | 3.2m | 8.5m | 9.1m |

## General and administrative expense | 6.5m | 11.3m | 12.2m |

## Operating expense total | 11.4m | 35.2m | 29.6m |

## EBIT | 7.1m | (21.2m) | 10.9m |

| 38% | (152%) | 27% |

## Interest expense | 20.0k | 437.7k | |

## Interest income | 20.0k | 144.7k | |

## Pre tax profit | 7.1m | (21.1m) | 11.4m |

## Income tax expense | 550.5k | 51.3k | (177.2k) |

## Net Income | 6.6m | (21.2m) | 11.6m |

USD | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 13.5m | 18.1k | 22.0k | 1.7m | 3.2m | 4.4m | 5.4m | 6.8m | 20.6m | 4.3m | 6.3m |

## Cost of goods sold | |||||||||||

## Gross profit | 6.8m | 20.6m | |||||||||

| 100% | 100% | |||||||||

## Sales and marketing expense | 1.2m | 84.4k | 141.0k | 1.1m | 1.7m | ||||||

## R&D expense | 344.8k | 1.1m | 1.6m | 2.4m | 1.6m | 1.9m | 3.6m | 1.6m | 1.8m | 1.4m | 558.3k |

## General and administrative expense | 1.4m | 2.0m | 4.0m | 3.0m | 2.9m | 3.4m | 3.7m | 3.7m | 3.2m | 2.6m | 2.8m |

## Operating expense total | 2.9m | 3.2m | 5.6m | 11.0m | 4.5m | 5.3m | 7.3m | 5.4m | 10.0m | 5.1m | 5.1m |

## EBIT | 10.6m | (3.2m) | (5.6m) | (9.3m) | (1.3m) | (940.0k) | (1.8m) | 1.4m | 10.6m | (1.7m) | (231.6k) |

| 79% | (17473%) | (25482%) | (547%) | (42%) | (22%) | (34%) | 21% | 51% | (40%) | (4%) |

## Interest expense | 877.0 | 10.7k | 7.0k | 122.0k | 112.0k | 76.6k | 11.5k | ||||

## Interest income | 877.0 | 10.7k | 7.0k | 5.0k | 6.0k | 20.0k | 122.0k | ||||

## Pre tax profit | 10.6m | (3.1m) | (9.3m) | (1.4m) | (918.0k) | (1.7m) | 1.5m | 10.7m | (1.6m) | (216.2k) | |

## Income tax expense | 33.0k | (57.0k) | 39.0k | ||||||||

## Net Income | 10.6m | (3.1m) | (5.6m) | (9.3m) | (1.4m) | (918.0k) | (1.7m) | 1.6m | 10.7m | (1.7m) | (216.2k) |

USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|

## Cash | 20.4k | 598.6k | 254.8k | 434.2k | 1.5m | 8.1m | 24.6m | 31.0m |

## Accounts Receivable | 312.5k | 11.7m | 4.5m | |||||

## Prepaid Expenses | 733.3k | 1.1m | ||||||

## Current Assets | 20.4k | 619.9k | 278.8k | 467.4k | 1.9m | 20.8m | 29.4m | 39.3m |

## PP&E | 6.5k | 1.2k | 243.0k | |||||

## Total Assets | 45.0k | 643.1k | 300.7k | 487.8k | 1.9m | 20.8m | 29.4m | 40.3m |

## Accounts Payable | 55.5k | 40.8k | 200.6k | 315.5k | 140.6k | 3.2m | 1.1m | 1.3m |

## Short-term debt | 4.3k | 5.6k | 7.0k | 165.0k | 10.3k | |||

## Current Liabilities | 883.1k | 2.0m | 3.6m | 4.2m | 5.7m | 9.8m | 5.6m | |

## Long-term debt | 254.7k | |||||||

## Total Debt | 4.3k | 5.6k | 7.0k | 165.0k | 9.8k | 254.7k | ||

## Total Liabilities | 663.7k | 1.6m | 3.4m | 8.9m | 6.6m | 7.8m | 12.5m | 5.9m |

## Common Stock | 126.1k | 164.7k | 178.2k | 1.8k | 2.0k | 2.5k | 3.8k | 4.2k |

## Additional Paid-in Capital | 23.2m | 27.4m | 43.1m | 45.0m | 56.5m | 66.2m | 91.3m | 97.2m |

## Retained Earnings | (46.3m) | (53.4m) | (61.2m) | (53.2m) | (74.4m) | (62.8m) | ||

## Total Equity | (618.7k) | (990.0k) | (3.1m) | (8.4m) | (4.7m) | 13.0m | 16.9m | 34.4m |

## Debt to Equity Ratio | 0 x | 0 x | ||||||

## Debt to Assets Ratio | 0.1 x | 0 x | ||||||

## Financial Leverage | -0.1 x | -0.6 x | -0.1 x | -0.1 x | -0.4 x | 1.6 x | 1.7 x | 1.2 x |

USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|

## Net Income | (12.4m) | (4.7m) | (11.5m) | (7.0m) | (7.8m) | 1.4m | (21.2m) | 11.6m |

## Depreciation and Amortization | 1.4k | 1.4k | 1.4k | 1.4k | 2.4k | 2.1k | 2.6k | 60.8k |

## Accounts Receivable | (312.5k) | (7.9m) | 7.2m | (2.7m) | ||||

## Accounts Payable | (48.6k) | (14.7k) | 159.8k | 114.9k | (174.9k) | 1.1m | (1.9m) | 361.2k |

## Cash From Operating Activities | (1.1m) | (747.3k) | (1.0m) | (4.2m) | (915.3k) | (3.8m) | (523.0k) | 4.1m |

## Purchases of PP&E | (7.5k) | (302.5k) | ||||||

## Cash From Investing Activities | (7.5k) | (302.5k) | ||||||

## Cash From Financing Activities | 1.1m | 1.3m | 661.5k | 4.4m | 2.0m | 5.1m | 17.0m | 2.6m |

## Net Change in Cash | (31.4k) | 578.2k | (343.9k) | 179.4k | 1.0m | 1.2m | 16.5m | 6.4m |

## Interest Paid | 6.7k | 257.8k | 78.9k | |||||

## Income Taxes Paid | 619.2k | 174.0k | 800.0 |

USD | Q1, 2012 |
---|---|

## Financial Leverage | -0.2 x |